Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the ...

Eli Lilly (NYSE:LLY) announced on Wednesday that its FDA-approved antitumor agent Verzenio, as part of a combination regimen, improved overall survival in a late-stage trial for certain patients with ...

Eli Lilly’s Verzenio (abemaciclib) boosted overall survival (OS) in the adjuvant breast cancer setting during a late-stage trial. In the Phase III monarchE study, (NCT02763566), Verzenio plus ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s Verzenio has proven it can extend patients’ lives in the indication. Verzenio ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone ...